Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting
WALTHAM, Mass., March 17, 2026 -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced an upcoming poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, taking place from April 17-22, 2026 at the San Diego Convention Center in San Diego, California.
Poster presentation details, as follows:
Title: Discovery and Optimization of XTX601, a Masked Claudin 18.2-Targeting T Cell Engager
Session Category: Immunology
Session Title: T Cell Engagers 1
Session Date and Time: Monday, Apr. 20, 2026, from 9:00 a.m. to 12:00 p.m. PST
Location: Poster Section 10
Poster Board: 11
Abstract Number: 1619
About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing masked immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. Leveraging our clinically-validated masking technology and capabilities, Xilio is developing I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents.
Cautionary Note Regarding Forward-Looking Statements
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Exchange Traded Funds Top 10 Volume Leaders
NET % VOL STOCK (Symbol) LAST CHG CHG 100s Direxion Semicon Br 3x SOXS 33.79 3.14 10.24 113,576,607 ProShares Bitcoin ETF BITO 10.93 -0.21 -1.89 112,012,221 Direxion Semicon Bl 3x SOXL 142.52 -16.39 -10.31 100,351,229 ProShares Sh Russell2001 RWM 14.43 0.01 0.07 77,482,048 GrShr 2x Sh NVDA Daily NVD 3.55 0.20 5.97 73,813,301 ProShares UltraPro QQQ TQQQ 80.23 -3.39 -4.05 65,485,124 ProSh UltraPro Shrt QQQ SQQQ 33.37 1.30 4.05 60,470,210 iShares Bitcoin Trust ETF IBIT 46.26 -0.95 -2.01 56,191,237 Direxion PLTR Bear 1X PLTD 4.50 -0.11 -2.39 52,552,250 SS Energy Sel SPDR XLE 65.24 1.88 2.97 50,492,628 (END) Dow Jones Newswires October 08, 2026 17:38 ET (21:38 GMT)
--Zoetis Keeps Quarterly Dividend at $0.53 a Share, Payable Dec. 1 to Holders of Record Oct. 30
04:46 PM EDT, 10/08/2026 (MT Newswires) -- Zoetis Keeps Quarterly Dividend at $0.53 a Share, Payable Dec. 1 to Holders of Record Oct. 30
Should You Buy Microsoft Stock (MSFT) in October? 3 Things Investors Need to Know
U.S. Fed weekly balance sheet
Oct 8 (Reuters) - For details of the Federal Reserve's balance sheet, see the following link: http://www.federalreserve.gov/releases/h41/Current/h41.pdf ((Washington newsroom))
Crypto prices
More
